• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

液体活检在卵巢癌中的应用。

Liquid biopsy in ovarian cancer.

机构信息

Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, University Campus, Athens, Greece.

Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, University Campus, Athens, Greece.

出版信息

Adv Clin Chem. 2020;97:13-71. doi: 10.1016/bs.acc.2020.01.001. Epub 2020 Feb 14.

DOI:10.1016/bs.acc.2020.01.001
PMID:32448432
Abstract

Ovarian cancer has the worst survival rate because it is typically diagnosed at advanced stage. Despite treatment, the disease commonly recurs due to chemo-resistance. Liquid biopsy, based on minimally invasive blood tests, has the advantage of following tumor evolution in real time, offering novel insights on cancer prevention and treatment. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating cell-free microRNAs (cfmiRNAs) and circulating exosomes represent the major components of liquid biopsy. In this chapter, we provide an overview of recent research on CTCs, ctDNA, cfmiRNAs and exosomes in ovarian cancer. We also focus on the clinical value of liquid biopsy in early diagnosis, prognosis, treatment response, as well as screening in the general population.

摘要

卵巢癌的存活率最差,因为它通常在晚期才被诊断出来。尽管经过治疗,由于化疗耐药,该疾病通常会复发。基于微创血液检测的液体活检具有实时跟踪肿瘤演变的优势,为癌症的预防和治疗提供了新的见解。循环肿瘤细胞(CTC)、循环肿瘤 DNA(ctDNA)、循环无细胞 microRNAs(cfmiRNAs)和循环外泌体是液体活检的主要组成部分。在本章中,我们概述了最近在卵巢癌中对 CTC、ctDNA、cfmiRNAs 和外泌体的研究。我们还重点介绍了液体活检在早期诊断、预后、治疗反应以及普通人群筛查中的临床价值。

相似文献

1
Liquid biopsy in ovarian cancer.液体活检在卵巢癌中的应用。
Adv Clin Chem. 2020;97:13-71. doi: 10.1016/bs.acc.2020.01.001. Epub 2020 Feb 14.
2
Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.液体活检在卵巢癌中的应用:循环 miRNA 和外泌体的潜力。
Transl Res. 2019 Mar;205:77-91. doi: 10.1016/j.trsl.2018.10.003. Epub 2018 Oct 12.
3
Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.液体活检在卵巢癌中的应用:循环肿瘤细胞和循环肿瘤 DNA 的最新进展。
Clin Chem Lab Med. 2018 Jan 26;56(2):186-197. doi: 10.1515/cclm-2017-0019.
4
Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?液体活检在卵巢癌中应用循环肿瘤 DNA 和细胞:是否已经准备好进入黄金时代?
Cancer Lett. 2020 Jan 1;468:59-71. doi: 10.1016/j.canlet.2019.10.014. Epub 2019 Oct 11.
5
Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.液体活检:癌症循环外泌体长非编码 RNA。
Clin Chim Acta. 2019 Aug;495:331-337. doi: 10.1016/j.cca.2019.04.082. Epub 2019 May 2.
6
The potential of liquid biopsy in the management of cancer patients.液体活检在癌症患者管理中的应用潜力。
Semin Cancer Biol. 2022 Sep;84:69-79. doi: 10.1016/j.semcancer.2022.03.013. Epub 2022 Mar 21.
7
Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.循环无细胞 DNA 和循环肿瘤细胞,卵巢癌的“液体活检”。
J Ovarian Res. 2017 Nov 13;10(1):75. doi: 10.1186/s13048-017-0369-5.
8
Liquid biopsy in breast cancer: A comprehensive review.乳腺癌中的液体活检:全面综述。
Clin Genet. 2019 Jun;95(6):643-660. doi: 10.1111/cge.13514. Epub 2019 Feb 27.
9
Circulating tumor cells as a "real-time liquid biopsy": Recent advances and the application in ovarian cancer.循环肿瘤细胞作为一种“实时液体活检”:最新进展及其在卵巢癌中的应用。
Taiwan J Obstet Gynecol. 2022 Jan;61(1):34-39. doi: 10.1016/j.tjog.2021.11.008.
10
Potential clinical utility of liquid biopsies in ovarian cancer.液体活检在卵巢癌中的潜在临床应用。
Mol Cancer. 2022 May 11;21(1):114. doi: 10.1186/s12943-022-01588-8.

引用本文的文献

1
Innovative Approaches to Early Detection of Cancer-Transforming Screening for Breast, Lung, and Hard-to-Screen Cancers.癌症早期检测的创新方法——乳腺癌、肺癌及难筛查癌症的转化性筛查
Cancers (Basel). 2025 Jun 2;17(11):1867. doi: 10.3390/cancers17111867.
2
Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives.揭示高级别浆液性卵巢癌(HGSOC)的耐药途径:最新进展与未来展望
Front Immunol. 2025 Apr 30;16:1556377. doi: 10.3389/fimmu.2025.1556377. eCollection 2025.
3
Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions.
卵巢癌的早期诊断:进展、挑战及未来方向综述
Diagnostics (Basel). 2025 Feb 7;15(4):406. doi: 10.3390/diagnostics15040406.
4
Profiling the metabolome of uterine fluid for early detection of ovarian cancer.对子宫液代谢组进行分析,以早期检测卵巢癌。
Cell Rep Med. 2023 Jun 20;4(6):101061. doi: 10.1016/j.xcrm.2023.101061. Epub 2023 Jun 1.
5
Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer.卵巢癌中循环肿瘤细胞的检测及循环肿瘤细胞上皮-间质转化模式的评估
Transl Cancer Res. 2022 Aug;11(8):2636-2646. doi: 10.21037/tcr-22-529.
6
Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer.卵巢癌中循环肿瘤DNA及配对腹水与肿瘤组织的突变分析
Exp Ther Med. 2022 Jun 30;24(3):542. doi: 10.3892/etm.2022.11479. eCollection 2022 Sep.
7
Detection of Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients.高级别浆液性卵巢癌患者原发性肿瘤和血浆游离DNA中突变的检测
Cancers (Basel). 2022 Aug 4;14(15):3790. doi: 10.3390/cancers14153790.
8
Extracellular MicroRNAs as Intercellular Mediators and Noninvasive Biomarkers of Cancer.细胞外微小RNA作为癌症的细胞间介质和非侵入性生物标志物
Cancers (Basel). 2020 Nov 20;12(11):3455. doi: 10.3390/cancers12113455.